Presented by Prof Dr Timothy Cloughesy (University of California Los Angeles, USA)
In this poster video, Prof Dr Timothy Cloughesy discusses updated results from the phase III INDIGO trial evaluating vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1/2, in patients with grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery. Patients enrolled in the study had measurable non-enhancing disease, had received no prior treatment other than surgery, and were not considered to require immediate radiotherapy or chemotherapy.1,2
At a median follow-up of 44.1 months, the trial continues to show a durable clinical benefit with vorasidenib. Median progression-free survival by blinded independent review was 44.1 months, and time to next intervention remained not reached. At 48 months, 74.2% of patients treated with vorasidenib had not required subsequent treatment with radiotherapy, chemotherapy or surgery. Tumour shrinkage also appeared to deepen gradually over time, with response rates increasing as the dataset matured. The updated safety profile remained consistent with previous reports, with no new safety signals. The most relevant grade ≥3 adverse events were liver enzyme elevations, including ALT, AST and GGT increases, occurring mainly during the first 12 months of treatment.1
The interview also highlights exploratory analyses on seizures and quality of life. Although patients with uncontrolled seizures were excluded, approximately one third of patients reported at least one seizure during the study. Vorasidenib was associated with a lower seizure burden compared with placebo, particularly in patients with oligodendroglioma, who generally have a higher seizure risk. In patients who experienced seizures, vorasidenib also delayed worsening of quality-of-life scores, including brain cancer-specific measures.2
References:
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in